Altamira Therapeutics Ltd
CYTO
CYTO was delisted on the 19th of December, 2024.
5 hedge funds and large institutions have $71.3K invested in Altamira Therapeutics Ltd in 2024 Q3 according to their latest regulatory filings, with 3 funds opening new positions, increasing their positions, reducing their positions, and 2 closing their positions.
2,314% more capital invested
Capital invested by funds: $2.95K → $71.3K (+$68.3K)
50% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 2
25% more funds holding
Funds holding: 4 → 5 (+1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
+$101K |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$14.7K |
| 3 |
DB
Danske Bank
Copenhagen K,
Denmark
|
+$1 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
-$1.9K |
| 2 |
Morgan Stanley
New York
|
-$1.04K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
AC
1
Armistice Capital
New York
| $61.9K | +$101K | +101,444 | New |
|
|
2
Citadel Advisors
Miami,
Florida
| $9.35K | +$14.7K | +14,802 | New |
|
3
Group One Trading
Chicago,
Illinois
| $9 | – | – | – |
|
|
DB
4
Danske Bank
Copenhagen K,
Denmark
| $1 | +$1 | +1 | New |
|
|
5
UBS Group
Zurich,
Switzerland
| – | -$1.9K | -1,711 | Closed |
|
|
6
Morgan Stanley
New York
| – | -$1.04K | -933 | Closed |
|
CYTO Hedge Fund Activity: Q3 2024 in Review
5 of the 6,964 institutional investors tracked by Wall St. Rank reported a position in Altamira Therapeutics Ltd (CYTO) for Q3 2024, worth a combined $71.3K — up 2,314% from $2.95K a quarter earlier.
Buyers outnumbered sellers: 3 funds opened new CYTO positions and 2 closed out — a net gain of 1 holder — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Armistice Capital, opening a new position worth an estimated $101K. The largest seller was UBS Group, exiting entirely with an estimated $1.9K sold.
- 5 institutional investors held Altamira Therapeutics Ltd (CYTO) as of Q3 2024, up from 4 in Q2 2024.
- Funds reported $71.3K of Altamira Therapeutics Ltd stock for Q3 2024, up 2,314% quarter-over-quarter.
- 3 funds opened new Altamira Therapeutics Ltd positions in Q3 2024 and 2 closed out, a net change of +1 holder.
- The largest Altamira Therapeutics Ltd buyer in Q3 2024 was Armistice Capital, an estimated $101K added.
- The largest Altamira Therapeutics Ltd seller in Q3 2024 was UBS Group, an estimated $1.9K sold.
Based on aggregated 13F filings for Q3 2024.